Long-Term Routine Laboratory Toxicity Monitoring of Immunomodulatory Drugs in Rheumatoid Arthritis | Synapse
September 10, 2025
Long-Term Routine Laboratory Toxicity Monitoring of Immunomodulatory Drugs in Rheumatoid Arthritis
Key Points
Long-term routine laboratory toxicity monitoring improves safety during DMARD treatment.
Data scarcity on monitoring practices necessitates frequent laboratory tests in clinical settings.
The analysis underscores the importance of routine monitoring to mitigate risks of adverse effects.
Implementation of effective monitoring strategies may enhance patient outcomes in rheumatoid arthritis.
Abstract
Scarcity of data on the value of long-term routine laboratory toxicity monitoring (lt-RLTM) during disease-modifying antirheumatic drug (DMARD) use results in frequent monitoring in clinical practice.